See the DrugPatentWatch profile for tazverik
What was Epizyme’s tazverik (tazemetostat) peak sales, and what estimate exists for 2022?
The provided information does not include any sales figures, forecasts, or “peak sales” estimates for Epizyme’s tazverik (tazemetostat) in 2022. Without source data (e.g., a specific report, analyst note, or filings excerpt), a credible peak-sales number for that year can’t be stated.
If you share the source you’re referring to (report name/link, table screenshot, or the exact text), I can extract the 2022 peak-sales estimate and summarize it clearly.
Where do “peak sales” estimates for oncology drugs usually come from?
Peak sales estimates are typically published by third-party research firms (for example, oncology-focused market research or equity research), or they are inferred from:
- projected patient numbers and uptake curves,
- dosing assumptions,
- pricing assumptions,
- line-of-therapy and geography assumptions,
- timeline assumptions around label expansion and competitor dynamics.
But those assumptions (and the resulting peak number) depend entirely on the specific study—so I’d need the underlying estimate to report the figure you want.
Was tazverik expected to reach peak sales around 2022?
Whether tazverik’s peak was expected near 2022 depends on the forecast horizon used by the estimate (some forecasts peg peak several years after initial uptake). Again, that requires the specific estimate or forecast source.
Quick way to get the exact number you’re looking for
Paste any of the following and I’ll pull out “peak sales estimate 2022” precisely:
- the analyst/report text around “peak sales,” “2022 sales,” or “tazemetostat peak revenue”
- a link to the report
- a screenshot of the forecast table
Sources
No sources were provided in your prompt, so I can’t cite any figures.